|
시장보고서
상품코드
2049498
내분비 검사 시장 보고서 : 검사 유형별, 기술별, 최종 용도별, 지역별(2026-2034년)Endocrine Testing Market Report by Test Type, Technology, End Use, and Region 2026-2034 |
||||||
세계의 내분비 검사 시장 규모는 2025년에 128억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 220억 달러에 달하고, 2026년부터 2034년까지 CAGR 6.02%로 성장할 것으로 예측했습니다.
내분비 검사는 체내 호르몬 농도를 측정하고 호르몬 관련 질환을 진단하기 위해 시행하는 의료 행위를 말합니다. 이 검사는 특정 만성 질환의 발병으로 이어질 수 있는 호르몬 농도의 불균형을 감지하는 데 도움이 됩니다. 이러한 질환의 검사에는 일반적으로 세침흡인생검(FNA), 초음파 검사, 컴퓨터단층촬영(CT), 자기공명영상(MRI), 양전자 방출 단층촬영(PET), 방사성요오드검사(RAI), 정맥채혈 등이 사용됩니다. 이렇게 얻은 검사 결과는 질병의 진행 상황을 판단하고 환자에게 시행하는 치료의 효과를 모니터링하는 데 도움이 됩니다.
부신기능부전, 쿠싱병, 거인증, 갑상선기능저하증, 갑상선기능항진증 등 내분비 관련 질환의 유병률 증가는 시장 성장을 견인하는 주요 요인 중 하나입니다. 또한, 건강 인식의 증가와 적시 검사의 이점에 대한 인식이 높아짐에 따라 시장 성장도 촉진되고 있습니다. 정기적인 검사는 특히 고령의 환자에서 합병증 발생 및 질병 악화 위험을 최소화합니다. 이에 따라 고령 인구의 증가도 시장 성장을 촉진하는 또 다른 주요 요인으로 작용하고 있습니다. 또한, 신종 코로나 바이러스(COVID-19)의 팬데믹으로 인해 감염 환자의 고혈당 검출을 위해 내분비 검사가 널리 활용되고 있습니다. 또한, 바이오센서를 탑재하여 사용자 친화적이고 비용 효율적인 재택 진단을 가능하게 하고, 조작이 간편한 혁신적인 검사 키트의 개발은 시장에 밝은 전망을 가져다주고 있습니다. 의료 시설, 검사실, 진단 센터에서는 고도로 정밀하고 정확한 결과를 제공하기 위해 기술적으로 진보된 액체 크로마토그래피-질량 분석(LC-MS) 기술을 채택하고 있습니다. 의료 인프라 개선 등 다른 요인들도 시장을 더욱 견인할 것으로 예상됩니다.
본 보고서에서 답변하는 주요 질문
- 지금까지의 세계 내분비 검사 시장의 동향은 어떠했으며, 향후 몇 년 동안 어떻게 변화할 것인가?
- COVID-19는 세계 내분비 검사 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은 어디인가?
- 검사 종류에 따른 시장 분석은 어떠한가?
- 기술별 시장 현황은 어떠한가?
- 최종 용도별 시장 내역은 어떠한가?
- 이 산업의 가치사슬에서 각 단계는 어떤 역할을 하는가?
- 이 산업의 주요 촉진요인과 과제는 무엇인가?
- 세계 내분비 검사 시장의 구조는 무엇이며, 주요 업체는 누구인가?
- 업계 내 경쟁은 어느 정도 치열한가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 내분비 검사 시장
제6장 시장 내역 : 테스트 유형별
제7장 시장 내역 : 기술별
제8장 시장 내역 : 최종사용별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSM 26.06.10The global endocrine testing market size reached USD 12.8 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 22.0 Billion by 2034, exhibiting a growth rate (CAGR) of 6.02% during 2026-2034.
Endocrine testing refers to the medical procedures conducted to measure the hormonal levels in the body and the diagnosis of hormone-related disorders. The testing aids in detecting an imbalance in the concentrations of hormones that may lead to the development of certain chronic conditions. These disorders are usually tested by fine-needle aspiration (FNA), ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI), positron emission test (PET), radioactive iodine scan (RAI) and venous sampling. The test results thus obtained can assist in determining the progression of the disorder and monitoring the effects of the treatment being provided to the patient.
The increasing prevalence of endocrine-related disorders, such as adrenal insufficiency, Cushing's disease, gigantism, hypothyroidism and hyperthyroidism, represents one of the key factors driving the growth of the market. Furthermore, the increasing health consciousness and awareness regarding the benefits of timely testing is providing a boost to the market growth. Periodic testing minimizes the risks of developing complications or aggravation of the disorder, especially in elderly patients. In line with this, the rising geriatric population is acting as another major growth-inducing factor. Moreover, due to the onset of the coronavirus (COVID-19) pandemic, endocrine testing is being widely used to detect hyperglycemia in infected patients. Additionally, the development of innovative easy-to-operate test kits equipped with biosensors that facilitate user-friendly and cost-effective home-based diagnosis is creating a positive outlook for the market. Healthcare centers, laboratories and diagnostic centers are also using technologically advanced liquid chromatography with mass spectrometry (LC-MS) techniques to provide highly precise and accurate results. Other factors, including improvements in the healthcare infrastructure, are anticipated to drive the market further.
KEY MARKET SEGMENTATION:
Breakup by Test Type:
- Thyroid Test
- Insulin Test
- Human Chorionic Gonadotropin Test
- Prolactin Test
- Luteinizing Hormone Test
- Progesterone Test
- Others
Breakup by Technology:
- Immunoassay
- Tandem Mass Spectroscopy
- Sensor Technology
- LC-MS
- Others
Breakup by End Use:
- Hospitals
- Ambulatory Care Centers
- Clinical Laboratories
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Agilent Technologies Inc., Bio-Rad Laboratories Inc., BioMerieux SA, DiaSorin S.p.A., F. Hoffmann-La Roche AG (Roche Holding AG), Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Siemens Healthineers AG (Siemens Aktiengesellschaft) and Thermo Fisher Scientific Inc.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global endocrine testing market performed so far and how will it perform in the coming years ?
- What has been the impact of COVID-19 on the global endocrine testing market ?
- What are the key regional markets ?
- What is the breakup of the market based on the test type ?
- What is the breakup of the market based on the technology ?
- What is the breakup of the market based on the end use ?
- What are the various stages in the value chain of the industry ?
- What are the key driving factors and challenges in the industry ?
- What is the structure of the global endocrine testing market and who are the key players ?
- What is the degree of competition in the industry ?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Endocrine Testing Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Test Type
- 6.1 Thyroid Test
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Insulin Test
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Human Chorionic Gonadotropin Test
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Prolactin Test
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Luteinizing Hormone Test
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Progesterone Test
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Others
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
7 Market Breakup by Technology
- 7.1 Immunoassay
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Tandem Mass Spectroscopy
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Sensor Technology
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 LC-MS
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by End Use
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Ambulatory Care Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Clinical Laboratories
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Agilent Technologies Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Bio-Rad Laboratories Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 BioMerieux SA
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 DiaSorin S.p.A.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 SWOT Analysis
- 14.3.7 Laboratory Corporation of America Holdings
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Quest Diagnostics Incorporated
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Siemens Healthineers AG (Siemens Aktiengesellschaft)
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Thermo Fisher Scientific Inc.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.1 Abbott Laboratories
